Business Wire

Dole Pineapple Workers Open Community Center Thanks to Fair Trade

Del

Dole Food Company and Fair Trade USA jointly announced today the inauguration of two new community centers near Dole’s Muelle and Bosque Farms in Costa Rica, made possible by Fair Trade purchases made at Whole Foods Market stores, which drive additional money to pineapple farmworkers to invest in projects of their choosing. The commencement events at the two locations took place on December 5th and 6th, 2017.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171214005458/en/

(Photo: Business Wire)

(Photo: Business Wire)

To earn Fair Trade certification, farms must adhere to rigorous social, environmental and economic standards. Once certified, farmworkers directly earn additional Community Development Funds with every purchase. They then vote on how to use the money to address their needs. This direct economic benefit is truly what makes Fair Trade unique, and is a process that takes time and dedication to be realized. The farms were Fair Trade Certified™ in the second half of 2012, requiring approximately four years of savings – as decided by the workers themselves – before breaking ground on the new facilities.

“I’ve had the privilege of visiting these Community Centers firsthand, and was moved by the dedication of the workers to this project and the quality of the facilities,” said Ken Redding, Chief Commercial Officer at Fair Trade USA. “Working together they identified a critical need, saved over time, and invested their Fair Trade Funds in a project that will serve the community for decades to come. That’s the Fair Trade Difference at work.”

Unique in the fresh fruit industry, these centers were built to improve the quality of life of employees, and those in surrounding communities of Cutris in San Carlos and Guacimo in Limon, Costa Rica.

“These facilities have become a reality thanks to the Fair Trade USA program,” said Renato Acuna, Dole President of Fresh Fruit Latin America. “This certification acknowledges that we are striving to increase farm worker empowerment, including leadership and organization of farm workers, economic development, and to ensure fair working conditions and environmentally responsible production methods. We are proud to have achieved this standard.”

Whole Foods Market is also a critical piece of the equation. As the main retailer and only National grocer in the U.S. offering these Fair Trade Certified pineapples from Costa Rica, their direct purchases have made the investment possible. These pineapples also meet Whole Foods Market’s Whole Trade Guarantee, which includes a 1% donation to Whole Planet Foundation for every purchase.

“Whole Foods Market is proud of our longstanding partnership with Dole in purchasing Fair Trade certified, Whole Trade Guaranteed Pineapples from Costa Rica,” said Kevin Doty, Senior Produce Coordinator for Whole Foods Market. “The Fair Trade premiums generated from the sales of these pineapples makes a positive impact on the lives of farm workers, their families, and communities. We are honored to be part of this special relationship and look forward to the continued success of programs like this.”

Education is a common need for many farming communities in Latin America. Previously the Fair Trade Committee at Dole’s La Virgen Farm built a community Education Center in 2013. A total of 344 people have graduated from the program: 150 adults in computer skills, 80 children in English and computer skills, 52 adults in English, 26 women in manicure/pedicure skills, 20 in handicraft classes, 12 in motorcycle repair, and 4 adults learned to read and write through an alphabetization program. Currently, there are an additional 263 people participating in several courses, including a high school program for adults, English, computer skills (Word/Excel), handicrafts (sewing, ceramics), and manicure/pedicure. 18 children are taking English and computer classes.

In addition to classrooms and computer rooms, the organic pineapple farm at La Virgen boasts a sporting facility, also built thanks to Fair Trade purchases. These facilities have been a powerful addition to community life.

A similar sports structure is projected to be built at centers supporting the Muelle and Bosque farm communities in the future.

About Dole Food Company

Dole Food Company, Inc., is one of the world’s largest producers and marketers of high-quality fresh fruit and fresh vegetables. Dole is an industry leader in many of the products it sells, as well as in nutrition education and research. For more information, please visit www.dole.com.

About Fair Trade USA

Fair Trade USA is a nonprofit organization that promotes sustainable livelihoods for farmers and workers; protects fragile ecosystems; and builds strong, transparent supply chains through independent, third-party certification. Its trusted Fair Trade Certified™ label signifies that rigorous standards have been met in the production, trade, and promotion of Fair Trade products from over 80 countries across the globe. Recognized as a leading social venture by the Clinton Global Initiative, the Skoll Foundation, and Ashoka, Fair Trade USA also provides critical capacity-building programs at origin, and educates consumers about the power of their purchase. Visit www.FairTradeCertified.org for more information.

Contact information

Dole US Contact:
William Goldfield, 818-874-4647
william.goldfield@dole.com
or
Fair Trade USA Contact:
Jenna LeDoux, 510-844-1668
jledoux@fairtradeusa.org

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10Pressemelding

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in

Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30Pressemelding

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr